DPP4 and diabetes mellitus: Further, both DPP4 and SGLT2 inhibitors have a lower risk of hypoglycaemia and potential cardiovascular and renal protective effects, while their impact on glycaemic control may not be as potent as that of sulfonylureas, particularly in patients who are more insulin-resistant or those with advanced diabetes.